Publication: Pharma's Almanac
Abstract
The Pharma’s Almanac article, “What are the biggest roadblocks still standing in the way of cell and gene therapy commercialization?”, provides in-depth insights into the challenges hindering the widespread adoption and commercialization of cell and gene therapies. Fran Brown, Ph.D., offers a Certara perspective, highlighting critical issues such as reduced investment interest, manufacturing scalability, cost limitations, safety concerns, and payer resistance. The piece emphasizes the need for innovative solutions, streamlined manufacturing processes, and better reimbursement frameworks to overcome these hurdles.
Year: September 2, 2025
Cell and Gene Therapy Services
Cell and gene therapies can treat, prevent, or potentially cure diseases at their genetic roots. However, the path from discovery to commercialization is complex. Certara’s integrated approach combines cutting-edge modeling and simulation, regulatory expertise, and market access strategies to guide you.
